Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a ...

Ford Is Taking on Expensive EVs and the Toyota RAV4 with Its New 'Model T'—a $30K Mid-Size EV Truck ‘What gives you the right ...

Known for producing companies like Karuna Therapeutics, which was sold to Bristol Myers Squibb for $14 billion, and newly ...

When a mental health crisis unfolds in Miami-Dade County, a call to 1-866-SAFEMIA brings a different kind of first responder.

Editas Medicine's shares are up in 2025, but the stock has lagged the market in recent years. The struggling biotech decided ...

Phase 1b/2a immune thrombocytopenia (ITP) trial FPI achieved, enrollment ongoing. Climb Bio is enrolling an open-label, dose-escalation Phase 1b/2a clinical trial of budoprutug in patients with ITP to ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Summit Therapeutics, which has consistently been communicating quarterly results through investor calls in the past few years ...

Using its hub-and-spoke business model, PureTech is launching a new company to develop deupirfenidone (LYT-100), its ...

Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the ...